Renasant Bio has raised $54.5 million in seed funding led by 5AM Ventures to develop disease-modifying treatments for ADPKD. The funding will support the progression of their lead programs targeting this genetic disorder.

Jul 10, 2025•23 days ago

Amount Raised

$54.5 Million

Round Type

seed

BerkeleyTherapeuticsBiotechnologyHealth Care

Investors

Qiming Venture Partners UsaOrbi MedAtlas Venture5 Am Ventures

Description

Renasant Bio has launched to advance treatments for autosomal dominant polycystic kidney disease (ADPKD). They have raised $54.5 million in seed funding, co-led by 5AM Ventures. The funding will support the company's pipeline of oral small molecule therapies. Renasant aims to address the underlying biology of ADPKD and halt disease progression.

Company Information

Company

Renasant Bio

Location

Berkeley, California, United States

About

Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends